Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866118 | 0.84 | POLB (0.67) | POLBMAPTPKMTP53HTT | |
| SCHEMBL8816723 | 0.76 | ATM (0.44) | PKMTP53HTTKMT2AMEN1 | |
| SCHEMBL6866981 | 0.75 | ATM (0.43) | MAPTPKMTP53HTTKMT2A | |
| SCHEMBL6862519 | 0.75 | POLB (0.56) | POLBMAPTPKMTP53HTT | |
| SCHEMBL3727778 | 0.72 | KMT2A (0.62) | POLBMAPTPKMTP53HTT | |
| SCHEMBL30969946 | 0.72 | KMT2A (0.62) | POLBMAPTPKMTP53HTT | |
| SCHEMBL6864158 | 0.69 | BCHE (0.46) | POLBMAPTTP53KMT2AMEN1 | |
| SCHEMBL20480423 | 0.68 | TDP1 (0.50) | — | |
| SCHEMBL9423961 | 0.68 | HDAC3 (0.51) | POLBMAPTPKMTP53HTT | |
| SCHEMBL595243 | 0.68 | ATM (0.69) | POLBMAPTPKMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803381-B1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS, ACTING AS ANTAGONISTS OR AGONISTS | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | claimed |
| US-6803381-B1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS, ACTING AS ANTAGONISTS OR AGONISTS | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-6596743-B2 | Control or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-6462198-B1 | USED IN THE CONTROL OR PREVENTION OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES, HEAD INJURIES, HYPOXIA, | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020091150-A1 | Carbamic acid derivatives | BLEICHER KONRAD (DE) | 2002-07-11 | — | — | US | disclosed |
| EP-1171423-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063166-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091150-A1 | Carbamic acid derivatives | CHRM1, CHRNA2, CHRM2 | POLB 737/4885MAPT 622/4885PKM 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.